Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

17.98B

Market cap17.98B

Price-Earnings ratio

14.09

Price-Earnings ratio14.09

Dividend yield

—

Dividend yield—

Average volume

1.76M

Average volume1.76M

High today

$92.50

High today$92.50

Low today

$90.21

Low today$90.21

Open price

$92.14

Open price$92.14

Volume

1.49M

Volume1.49M

52 Week high

$112.29

52 Week high$112.29

52 Week low

$53.56

52 Week low$53.56

Stock Snapshot

Incyte(INCY) stock is priced at $90.30, giving the company a market capitalization of 17.98B. It carries a P/E multiple of 14.09.

As of 2026-03-29, Incyte(INCY) stock has fluctuated between $90.21 and $92.50. The current price stands at $90.30, placing the stock +0.1% above today's low and -2.4% off the high.

Incyte(INCY) shares are trading with a volume of 1.49M, against a daily average of 1.76M.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

INCY News

TipRanks 8h

Incyte announces new 54-week data on safety, efficacy of povorcitinib

Incyte (INCY) announced 54-week data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 inhibitor, from the pivota...

Simply Wall St 2d

The Bull Case For Incyte Could Change Following Its U.S. Commercial Leadership Shake-Up – Learn Why

Earlier this week, Incyte reshaped its leadership team, elevating Pablo J. Cagnoni, M.D., to President and Global Head of R&D, expanding Steven Stein, M.D.’s re...

TipRanks 3d

Incyte Announces Major Executive Leadership and Commercial Reorganization

An announcement from Incyte ( (INCY) ) is now available. On March 25, 2026, Incyte announced a series of executive leadership changes designed to support its s...

Analyst ratings

50%

of 28 ratings

Buy

39.3%

Hold

50%

Sell

10.7%

More INCY News

Simply Wall St 4d

Incyte Leadership Shift And Dermatology Data Shape Investment Case

Incyte (NasdaqGS:INCY) has appointed Pablo J. Cagnoni, M.D. as President and Global Head of R&D, alongside other executive changes aimed at tighter integration...

TipRanks 4d

Incyte price target lowered to $94 from $104 at UBS

UBS lowered the firm’s price target on Incyte (INCY) to $94 from $104 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source...

TipRanks 4d

Incyte appoints Stein as Chief Medical Officer, Issa as EVP

Incyte (INCY) announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Steven Stein, M.D....

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

AMD

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.